CASE REPORT
Hepatitis B Reactivation with Fulminant
Hepatitis During Rituximab Chemotherapy
in a Patient with Follicular Lymphoma
More details
Hide details
1
Selcuk University Meram Medical Faculty, Konya, Turkey
Publication date: 2010-01-12
Corresponding author
Kadir Acar
Selcuk University Meram Medical Faculty,
Department of Hematology, Konya,
Turkey
Eur J Gen Med 2010;7(1):92-93
KEYWORDS
ABSTRACT
A 52-year-old man was diagnosed Follicular lymphoma with
autoimmune hemolytic anemia. At time of diagnosis his HBs Ag
was (+), Anti-HBs (-), and HBV DNA was negative. Chemotherapy
was interrupted after tree cycles of R-CVP due to elevated liver
enzyme. At that time HBV DNA became positive. Lamivudine
therapy was started, whereas patient died due to fulminant hepatic
failure. The high morbidity and mortality of this complication is
one of the major obstacles to completing the standard treatment
for lymphoma in HBV carriers. Thus, preventive therapy with
nucleoside or nucleotide analogs should be started before the
chemotherapy to prevent HBV reactivation.